Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world
The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric’s global network
BOSTON and SAN DIEGO, Jan. 15, 2024 /PRNewswire/ — Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally.
Related news for (ILMN)
- Illumina advances personalized cancer care with new pharma development partnerships
- Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025
- Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina
- Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company’s multiomics strategy
- Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis